Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
GSK-3 inhibitor 3
Cat. No.:
0225LY-1466
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
GSK-3 inhibitor 3 is an orally active, brain-permeable agent that targets GSK-3α and GSK-3β; it is particularly useful in Alzheimer's research for reducing tau protein phosphorylation.
Synonym:
2227279-84-5
CAS No.:
2227279-84-5
Compound CID:
134556469
Formula:
C23H15FN6
Formula Weight:
410.4
Specification
Targets&IC50:
CDK2: 0.22 μM; GSK-3α: 0.35 nM; CDK5: 1.3 μM; GSK-3β: 0.25 nM
Relative Density:
1.41 g/cm3 at 20°C.
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GSK-3 inhibitor 3 can be used in cell signaling research to explore the regulation of the Wnt/beta-catenin pathway and its role in development.
Library Information
Target:
GSK-3
Receptor:
GSK-3; tau
Pathways:
Stem cell regulation; Cytoskeletal signaling; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-19
Plate Location:
g9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
5.63 mg/mL; 13.72 mM
